Durect DRRX 深 沪
等待开盘 08-19 09:30:00 美东时间
1.90
-0.010
-0.52%
华盛通- 最 高1.92
- 今 开1.89
- 成交量 77.84万股
- 最 低 1.88
- 昨 收 1.91
- 总市值 5898.09万
- 52周最高 2.64
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.4801
- 委 比 85.04%
- 总股本 3104.26万
- 历史最高 39.49
- 量 比 1.99
- 振 幅 2.09%
- 历史最低 0.4703
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bausch Health To Acquire DURECT For $63M, Or $1.75 Per Share Upfront In All-Cash Deal, With Potential $350M In Milestone Payments
Recent business highlights and updates:In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with Bausch Health Americas, Inc. (Bausch Health Americas), a wholly owned subsidiary of
08-13 04:51
Durect Q2 EPS $(0.07) Beats $(0.11) Estimate, Sales $447.000K Beat $310.000K Estimate
Durect (NASDAQ:DRRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent. This is a 41.67 percent increase over losses of $(0.12) per share from the same
08-13 04:36
Durect Extends Tender Offer Deadline in Merger
Durect ( ($DRRX) ) has shared an announcement. On July 28, 2025, Durect Corpora...
08-09 05:47
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NSC, SNV, DRRX, PNFP on Behalf of Shareholders
NEW YORK, July 31, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
08-01 08:57
Reported Earlier: Bausch Health To Acquire DURECT And Its FDA Breakthrough Epigenetic Modulator Larsucosterol For Alcoholic Hepatitis In $63M Deal Plus Milestones
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic
07-29 21:56
Durect Merges with Bausch Health for $1.75/Share
Durect ( ($DRRX) ) just unveiled an update. On July 28, 2025, DURECT Corporatio...
07-29 19:56
Durect Receives Nasdaq Delisting Notice Extension
Durect ( ($DRRX) ) has issued an update. DURECT Corporation received a notice f...
07-12 05:02
Analysts Offer Insights on Healthcare Companies: I-MAB (IMAB) and Durect (DRRX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
05-18 01:40
Durect Q1 EPS $(0.13) Misses $(0.12) Estimate, Sales $321.00K Beat $291.67K Estimate
Durect (NASDAQ:DRRX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 48 percent increase over losses of $(0.25) per share from the same
05-14 04:23
Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Durect (DRRX ...
03-30 16:15
